ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO493

Patient-Reported Outcome Measures (PROMs) and Expanded Hemodialysis (HDx) with Medium Cut-Off Dialyzers in a Large Cohort of Patients in Colombia: The COREXH Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Sanabria, Mauricio, RTS, Bogotá, Colombia
  • Rivera, Angela S., Baxter Healthcare Corporation, Deerfield, Illinois, United States
  • Bernardo, Angelito A., Baxter Healthcare Corporation, Deerfield, Illinois, United States
  • Nilsson, Lars-Goran, Baxter International Inc., Lund, Sweden
  • Vesga, Jasmin, RTS, Bogotá, Colombia
  • Bunch, Alfonso, RTS, Bogotá, Colombia
  • Sanchez, Ricardo, Universidad Nacional de Colombia, Bogotá, Colombia
Background

Increasing importance and focus have been directed towards quality of life measures (QoL) and patient experience in end stage kidney patients on hemodialysis (HD). A new therapy, expanded hemodialysis(HDx) with Theranova membane improved clearance of middle molecular uremic toxins but to date its effects of QoL are lacking

Methods

Historical cohort, multicenter study in prevalent patients older than 18 years under the HDx therapy with MCO membrane that complete the twelve months of follow up in the COREXH Registry, in Renal Therapy Services (RTS) Colombia network. PROMs were assessed by KDQOL-36, Dialysis Symptoms Index (DSI), and diagnostic criteria for Restless Legs Syndrome (RLS) tools. The ANOVA and Cochran’s Q test was used.

Results

Out of 992, the 619 men (62.4%) with mean age 60.4±15.7 years. For KDQoL 36 domains, symptoms, burden and effects of kidney disease and mental component, significant increase in score at 6 and 12 mos was noted ( Table1 ). ANOVA for DSI shows statistically significant differences in mean severity scores over the follow-up with improvement from 30.7, 29.9 and 28.5 at baseline, six months and one year respectively, (F (2, 1450) = 6.92, p = 0.0087)). The proportion of patients with RLS scores improved from 22.11% at baseline, to 12.47% at 6 m and 9.98 at 12 m (Cochran’s Q, 2 df) = 145.42, p < 0.0001.

Conclusion

In this large multicenter study, HDx with Theranova resulted in improved patients’ related outcomes.

Patient Reported Outcome Measures
KDQoL – 36 domainsBaseline
(N=971)
Mean (SD)
At Six Months
(N=808)
Mean (SD)
At Twelve Months
(N=642)
Mean (SD)
p-Value
Sympton/Problem Domain78.6 (15.8)81.0 (15.4)81.5 (14.9)< 0.0001 *
Effect of Kidney Disease69.7 (22.03)72.8 (22)75.1 (21)< 0.0001*
Burden of Kidney Disease46.2 (27.5)48.9 (29.9)50.2 (32.3)< 0.0012*
SF-12 Physical41.1 (11.1)41.0 (11.2)41.7 (10.5)0.27*
SF-Mental51.1 (11.6)51.9 (11.3)52.3 (11.1)< 0.0016*
     
DSI30.7 (22.3)29.9 (32)28.5 (21.7)0.0087 *
     
RLS    
% of patients with RLS22.112.479.98< 0.0001**
     

* Anova test ** Cochran’s Q test KDQOL-36: Kidney Disease Quality of Life-36 DSI: Dialysis Symptoms Index RLS: Diagnostic criteria for Restless Legs Syndrome

Funding

  • Commercial Support